Inhaled particles (from cigarette smoke and other sources) cause lung inflammation. Chronic inflammation leads to structural changes and narrowing of the small airways, and these changes increase with disease severity.

Systemic inflammation is now a recognized factor for other complications commonly observed in COPD patients.

INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is a major public health problem and a leading cause of morbidity and mortality worldwide. It is characterized by persistent progressive limitations in airflow and the presence of emphysema and/or bronchitis. Inhaled particles (from cigarette smoke and other sources) cause lung inflammation. Chronic inflammation leads to structural changes and narrowing of the small airways, and these changes increase with disease severity. Systemic inflammation is now a recognized factor for other complications commonly observed in COPD patients.

Background: Chronic obstructive pulmonary disease (COPD) is associated with a progressive loss of muscle mass and function and a systemic inflammatory process that can cause sarcopenia. Objective: The objective of this study is to estimate the prevalence rate of sarcopenia in COPD patients and to determine the factors associated with sarcopenic patients living in Western Greece. Methods: European Working Group on Sarcopenia in Older People criteria were applied to 69 outpatients with stable COPD. Body composition, exercise capacity, functional performance, physical activity, and health status were also assessed. COPD disease severity (COPD stage) was evaluated with the Global Initiative for chronic obstructive lung disease. The study protocol was approved by the Ethical Committee of the Technological Educational Institute of Western Greece. Results: The sample comprised 69 patients (59 women and 10 men), with a mean age of 71.33 ± 7.48 years. The prevalence of sarcopenia was 24.6% (n = 17). A high percentage (82.6%; n = 57) of the 69 Greek participants did not perform any regular exercise. The findings of this study demonstrated that sarcopenia was positively associated with COPD, age, body mass index, skeletal muscle mass, hand grip strength, and 4 m test. Conclusions: In conclusion, there is a 24.6% prevalence of sarcopenia in patients with COPD. Further research with larger samples would be indicated to clarify the precise association of specific characteristics of patients with sarcopenia and COPD.

KEY WORDS: Airway obstruction, lung disease, sarcopenia, skeletal muscle mass

Address for correspondence: Dr. Maria Tsekoura, Department of Physiotherapy, School of Health Rehabilitation Sciences, University of Patras, Patras, Greece. E-mail: mariatsekoura@hotmail.com

Submitted: 12-Mar-2020 Revised: 19-May-2020 Accepted: 27-Jun-2020 Published: 30-Oct-2020

How to cite this article: Tsekoura M, Tsepis E, Billis E, Gliatis J. Sarcopenia in patients with chronic obstructive pulmonary disease: A study of prevalence and associated factors in Western Greek population. Lung India 2020;37:479-84.
including atherosclerosis, osteoporosis, cachexia, and muscle wasting. Sarcopenia is a disease which describes age-related muscle mass loss and muscle strength decline and is comprised multiple factors, including inflammation and chronic illness. A substantial body of the literature has demonstrated that inflammation cytokines activate many of the molecular pathways involved in skeletal muscle wasting leading to an imbalance between protein synthesis and catabolism. COPD can be considered a risk factor for sarcopenia in response to increased catabolism, elevated proinflammatory cytokines, and increased oxidative stress.

COPD prevalence varies across countries and across different population groups. Few studies in the literature have examined the association between the prevalence of sarcopenia and indices of COPD severity. The prevalence of COPD in sarcopenic patients ranged from 4.4% to 86.55%, due to variability in the various diagnostic tools, different reference values, and cutoffs presented in the literature. The prevalence and burden (economic and social) of COPD are expected to increase in the coming decades due to the continuous risk factors (tobacco smoking and air pollution) and aging of the world’s population. Although recognizing the prevalence and diagnostic methods of COPD and sarcopenia is a very important effort in the search of effective strategies of prevention and intervention, no studies have been conducted with Greek sample. Thus, the objective of this study was to investigate the prevalence of sarcopenia in COPD Greek patients and determine the risk factors associated with sarcopenia in patients with COPD.

**METHODS**

**Study design and population**

This was a cross-sectional study involving 69 consecutive COPD patients, all over 50 years of age. Participants were recruited from the region of Achaia and Ilia, mainlands in Western Greece. The assessment procedure was all carried out at the University of Patras (University Hospital of Patras and Physiotherapy department) between March and December of 2018.

All measurements were completed in a single visit for each participant. The exclusion criteria included (a) cognitive impairment, (b) pacemaker fitted, (c) lower leg trauma and/or amputation, (d) medical or other musculoskeletal problems that could affect ability to complete objective assessments, (e) lung rejection or transplantations, and (f) body mass index >50.

**Definition**

Patients diagnosed with COPD on the basis of past history and spirometric data according to the Global Initiative for chronic obstructive lung disease were eligible for this study. These criteria were characterized by persistent airflow limitation and a postbronchodilator force-expiratory volume in 1 s (FEV1) <70% of forced vital capacity. Sarcopenia was identified using a combination of Hand Grip Strength (HGS), skeletal muscle mass index (SMMI), and gait speed measurements according to the criteria presented in the European Working Group on Sarcopenia in Older People (EWGSOP). The EWGSOP presented a European consensus on the definition and diagnosis of sarcopenia in 2010, which was updated in 2018 by EWGSOP2. In EWGSOP2, low muscle strength is defined as the first parameter of sarcopenia, and the diagnosis is confirmed by the presence of decreased muscle mass (quantity and quality). The following cutoff values were used to identify sarcopenia: Handgrip strength of <27 kg for men and <16 kg for women and either SMMI of ≤7 kg/m² for men and ≤5.5 kg/m² for women, and or a gait speed of <0.8 m/s.

**Assessments – Procedure**

After consent, baseline patient data were collected by trained clinical researcher (MT). Each participant was interviewed face-to-face to assess his/her history of smoking, lifestyle habits, exercise habits, and medication use. Participants also completed a Mini-Mental State Examination (MMSE), which consisted of a 30-point questionnaire to assess their cognitive function. MMSE has been validated and extensively used in both clinical practice and research. Severity of COPD was measured through spirometry. Patients were asked to inhale as deep as they could and then exhaled into the sensor as hard as possible, for 6 s. Spirometry was repeated at least three times and up to a maximum of eight times to ensure the reproducibility and validity of results. Spirometry was performed according to the 1994 American Thoracic Society recommendations using the same type of dry rolling-seal spirometer (model SP10; CONTEC Medical Systems Co., LTD) for all of the participants.

HGS strength was measured using a hand-held dynamometer (Saehan corporation, Seoul, Korea). The researcher asked the patient to squeeze the dynamometer with maximal isometric strength for 5s. The procedure was carried out with the elbow flexed and by the side of the body. The best of three attempts was recorded.

Body composition was estimated using bioelectrical impedance analysis (BIA), with a Tanita BC 601 model body analysis monitor. Participants removed their socks, stood on two metallic electrodes on the floor scale barefoot, and held two metallic grip electrodes placed in the palm of their hand with their fingers wrapped around the handrails.

Skeletal muscle mass (SMM, kg) was estimated using whole body BIA and SMMI calculated as SMM/height². Fat free mass (FFM) was extracted by BIA and SMM values,
using the following equation: SMM (kg) = 0.566 × FFM. Participants were recommended to empty their bowel within 30 min before the measurement, and also not consume any meals and alcoholic beverages for at least 48 h before the tests.[12,13]

Gait speed was measured with the 4 m test. Participants were informed to walk 4 m with their maximal speed. The procedure was fully explained before the assessment followed by a familiarization attempt. For the 4 m test, time in seconds was the recorded variable.

**Statistical analysis**

Descriptive statistics were reported using means, standard deviations, and frequencies for patients’ characteristics. The effects of factors associated with sarcopenia were evaluated using the regression analysis. *T*-test for independent samples was used to determine the differences between the participants with sarcopenia and participants with no sarcopenia. Statistical significance was accepted at *P* ≤ 0.05 and adjusted odds ratio and 95% confidence interval were reported to consider the strength of association between the variables. Statistical analysis was performed with the SPSS Statistics Software Package, version 20.0 (IBM Corporation, Armonk, NY, USA).

The study protocol was approved by the Ethical Committee of the Technological Educational Institute of Western Greece.

**RESULTS**

The sample consisted of 69 patients (59 women and 10 men), with a mean age of 71.33 ± 7.48 years and a mean BMI of 26.09 ± 4.13 kg/m². Most of the patients were ex-smokers (79.7%; *n* = 55). Four patients (5.8%) were current smokers at enrollment in the study. The characteristics of the study population are shown in Table 1.

**Table 1: Differences between chronic obstructive pulmonary disease with sarcopenia and no sarcopenia**

| Variable                  | Sarcopenia (*n*=17) | No sarcopenia (*n*=42) | *P*   |
|---------------------------|--------------------|------------------------|-------|
| Age (years)               | 71.82±6.31         | 71.17±7.87             | NS    |
| Drug (n)                  | 3.35±1.32          | 2.3±1.6                | 0.01  |
| Comorbidities (n)         | 2.58±1.12          | 2.11±1.13              | NS    |
| BMI (kg/m²)               | 21.67±2.32         | 27.54±3.52             | <0.001|
| HGS (kg)                  | 16.27±3.1          | 21.86±6.35             | <0.001|
| SMMI                      | 5.51±0.21          | 7.4±1.74               | <0.001|
| 4 m test (s)              | 4.68±0.86          | 3.97±1.11              | 0.02  |
| Smoking status, n (%)     |                    |                        |       |
| Smokers                   | 2 (11.8)           | 8 (15.4)               | NS    |
| Ex-smokers                | 14 (82.4)          | 41 (78.8)              |       |
| Nonsmokers                | 1 (5.9)            | 3 (5.8)                |       |
| Regular physical activity, n (%) |                  |                        |       |
| Yes                       | 2 (11.8)           | 10 (19.2)              | NS    |
| No                        | 15 (88.2)          | 42 (80.8)              |       |

NS: Nonsignificant differences, BMI: Body mass index, SMMI: Skeletal Muscle Mass Index, HGS: Hand Grip Strength, 4 m test: 4 m test, COPD: Chronic Obstructive Pulmonary Disease, SD: Standard deviation

On the basis of the FEV1 values, the degree of obstruction was classified as mild in 14 (20%) of the patients, moderate in 31 (55.7%), severe in 14 (20%), and very severe in 10 (14.3%).

The prevalence of sarcopenia among COPD patients is 24.6% (*n* = 17). The mean SMMI was 5.51 ± 0.21 in the patients with sarcopenia (5.51 ± 0.21 in women and 6.65 ± 0.25 in men), compared with 7.4 ± 1.74 in those without (6.89 ± 1.2 in women and 9.57 ± 2.05 in men), the difference between the two groups being statistically significant (*P* < 0.001).

The comparison of the risk factors between sarcopenic and nonsarcopenic patients with COPD is shown in Table 2. The findings of this study demonstrated that sarcopenia was positively associated with BMI, SMMI, HGS, 4 m test, and negatively associated with smoking, age, regular physical activity, gender, comorbidities, and falls.

**DISCUSSION**

To our knowledge, this is the first study to examine sarcopenia in COPD in Greece. The overall prevalence of sarcopenia was 24.6%, which is consistent with the literature on COPD patients, in which the most reported prevalence is 20%–40%.[14,15] As observed, the prevalence of sarcopenia in COPD patients is higher than that in the normal elderly people. According to the Korean National Health and Nutrition Examination Survey, 13.4% of the population aged 40 years or older has COPD.[16] Sarcopenia is frequently observed in COPD patients, with varying prevalence across populations.[17] This variation is likely to be due to the differences in the criteria used for the assessment of sarcopenia. In the present study, the diagnosis of sarcopenia was performed using the EWGSOP criteria. Considering that the prevalence of sarcopenia in COPD patients is higher than that in normal elderly people,[16] and that the loss of muscle strength, muscle mass, and function may lead to decreases in physical activity and energy consumption, COPD may be among the possible causes of sarcopenia.[18-20] However, sarcopenia in COPD should be assessed using standardized tests and cutoff points from sarcopenia consensus criteria for clinical practice and international comparisons.[17] Estimating the overall prevalence of sarcopenia in line with the contemporary operational definitions will provide further insight into its burden in COPD.

According to EWGSOP, sarcopenia is “secondary” when another factor besides aging is present. EWGSOP state that secondary sarcopenia can occur due to a systemic disease such as COPD.[6] However, there is not any distinction in the recommendations of methods and cutoffs for distinguishing primary and secondary sarcopenia. Further understanding of the main molecular and cellular mechanisms underlying the onset of sarcopenia in COPD patients could support the optimization of assessment tools for sarcopenia in COPD.[17]
Further studies are needed to clarify the relationships between smoking history, comorbid diseases, and sarcopenia. The positive association found in the present study indicates that early diagnosis of sarcopenia can be beneficial for future studies.

However, Marino et al. [24] found that there was no association between HGS and spirometric lung function results, as assessed by the predicted forced expiratory volume percent in 1 s among participants with moderate-to-very severe COPD. In a Korean national survey, HGS was not significantly different between adults with and without COPD and was not associated with the degree of airflow limitation. In patients with COPD, the risk factors for decrease in muscle strength and endurance include chronic inflammation, oxidative stress, inactivity, hypoxemia, hormone abnormality, deficits of nutrients including protein and Vitamin D, and the use of systemic corticosteroid. Further studies are needed to clarify the actual status of HGS and the prevalence rates of sarcopenia in different aged groups in patients with COPD.

In the sample of COPD Greek patients, there was a high prevalence of diagnosed sarcopenia, which may be related to the poor prognosis. Recent data demonstrate that in patients with COPD, various factors such as specific unfavorable changes in body composition have been shown to be associated with a worse prognosis. Hence, a reduction in lean mass, which leads to exercise intolerance could contribute to those body composition changes. These factors may increase the frequency of exacerbations/hospital admissions and may increase mortality. This study supports the inclusion of body-composition assessment in COPD patients.

There were the six factors associated with sarcopenia using the regression analysis: COPD, BMI, number of drugs, SMMI, HGS, and 4 m test. As it had been expected, sarcopenia has significant associations with HGS, SMMI and 4 m test because they are the diagnostic criteria. In the literature, review factors associated with sarcopenia in COPD patients included nutritional status, exercise capacity, severity of COPD, functional performance, smoking status, comorbid diseases, and self-reported hospital admission. The positive association of sarcopenia with COPD indicates that early diagnosis of sarcopenia can facilitate the implementation of interventions aimed at preventing the deterioration of lean body mass and improving the quality of life in patients with COPD. A more holistic approach of COPD is essential rather than focusing only on airflow limitations. Future work should also address how sarcopenia can be optimally managed within respiratory disease.

A high percentage (82.6%; n = 57) of the 69 Greek participants answered that they did not perform any regular exercise. As the amount of activity decreases, muscle mass may decrease and eventually oxygen cannot be used effectively, resulting in a vicious cycle of deterioration of exercise capacity. Exercise could have beneficial effects in muscle quantity and quality (strength, mass, and functional performance) in patients with sarcopenia. It seems important to choose the exercise method according to the COPD status and help those patients. Although there is no significant association of regular exercise with sarcopenia among Greek participants, it is important to notice that physical activity was not measured with either accelerometer of a validated instrument, but it was based on a simple answer, whether they exercised or not. Certainly, addressing this would be beneficial for future studies.

Due to the high prevalence of COPD and sarcopenia, exercise and pulmonary rehabilitation programs should be performed aimed at maintenance or improvement of physical and nutritional condition of individuals with COPD. The assessment of patients’ muscle strength and body composition is important to provide them an appropriate treatment and follow-up their progress during pulmonary rehabilitation programs. Our results agree with the recommendation of the Asian Working Group for Sarcopenia, that people with COPD are recommended for sarcopenia screening and assessment.

In this study, the main percentage of participants were ex-smokers (79.7%) and 4 current-smokers. Although tobacco smoking is the main cause of COPD, it is also a known risk factor for many nonpulmonary diseases. It is well-known that even nonsymptomatic smokers can exhibit fatigability and reduced muscle resistance. This can be well explained by the anorectic effects of tobacco, which may lead to the loss of muscle mass, as well as inducing inflammation, oxidative stress, an imbalance between protein synthesis, and degradation in the muscle. In the present study, no significant association between smoking history and sarcopenia was recorded. In
support of a negative association, two studies did not find the differences in smoking across COPD patients with and without sarcopenia. One possible explanation for the present finding is that the majority of patients with COPD had a mild obstruction. Although there is controversy in the literature, one study demonstrated an association between smoking history and a loss of lean mass in COPD patients, whereas others do not confirm this finding.

Limitations of this study initially include the relatively small size of our sample. Further research with larger samples would be indicated. Future studies must also include age-matched controls to see the effect of COPD on sarcopenia. Second, muscle mass was assessed with BIA, a widely adopted method, but not the “gold standard.” However, BIA is a noninvasive, quick, safe, and inexpensive method of measuring body composition. It has been reported in an increasing number of studies over the past decade. In addition, the European Group on Sarcopenia in Older People accepts BIA as an option for sarcopenia assessment. In this study, the formula which was used (SMM [kg] =0.566 × FM) was validated on individual and group data and has been compared with SMM data calculated from 24 h creatinine excretion in a group of healthy participants as well. The European Working Group on Sarcopenia in Older Persons (EWGSOP) criteria accept the use of BIA and has been reported in an increasing number of studies over the past decade. Third, the vast majority of patients were women, and hence, the results might not be representative of the population. More research is needed to clarify the precise association of specific characteristics of patients with sarcopenia and COPD.

CONCLUSIONS

In conclusion, there is a 24.6% prevalence of sarcopenia in patients with COPD. Sarcopenia is associated with reduced muscle strength, skeletal muscle mass, gait speed, BMI, and COPD. Further large-scale research, including aged-matched groups, is needed to confirm the results of this study aiming to improve our understanding of determinants of sarcopenia in patients with COPD.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Caria KR, Camelier FW, Cordeiro N, Moreira AV, Santos BS, Camelier AA. Prevalence of sarcopenia in chronic obstructive pulmonary disease: Systematic review. J Phys Res 2018;8:564-78.
2. Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis 2017;12:669-75.
3. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
4. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008;31:492-501.
5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412-23.
6. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019;48:16-31.
7. Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: The effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014;2:819-29.
8. Meng SJ, Yu LJ. Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci 2010;11:1509-26.
9. Costa TM, Moreira CA, Rabelo LM, Boguszewski CL, Borba VZ. Sarcopenia in COPD: Relationship with COPD severity and prognosis. J Bras Pneumol 2015;41:415-21.
10. Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: Prevalence, clinical correlates and response to pulmonary rehabilitation. Thorax 2015;70:213-8.
11. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Tsekoura M, Billis E, Tsepis E, Dimitriadis Z, Matzaroglou C, Tyllianakis M, et al. The effects of group and home-based exercise programmes in elderly with sarcopenia: A randomized controlled trial. J Clin Med 2016;7:480.
13. Bahat G, Tufan A, Tufan F, Kilic C, Akpinar TS, Kose M, et al. Cut-off points to identify sarcopenia according to European Working Group on Sarcopenia in Older People (EWGSOP) definition. Clin Nutr 2016;35:1557-63.
14. Lee DW, Choi EY. Sarcopenia as an independent risk factor for decreased BMD in COPD patients: Korean national health and nutrition examination surveys IV and V (2008-2011). PLoS One 2016;11:e0164303.
15. Marquis K, Debigaré R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-13.
16. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: The fourth Korean National Health and Nutrition Examination Survey. 2008. Reporology 2011;16:659-65.
17. Benz E, Trajanońska K, Lahousse L, Schoufour JD, Terzikhan N, De Roos E, et al. Sarcopenia in COPD: A systematic review and meta-analysis. Eur Respir Rev 2019;28:190049.
18. Limparawattana P, Putraweevong S, Ithasawun P, Boonsawat W, Theerakulpisut D, Chinaprasit J. Frailty syndrome in ambulatory patients with COPD. Int J Chron Obstruct Pulmon Dis 2017;12:1193-8.
19. Kim SH, Shin MJ, Shin YB, Kim KU. Sarcopenia associated with chronic obstructive pulmonary disease. J Bone Metab 2019;26:65-74.
20. Jang HC. How to diagnose sarcopenia in Korean older adults. Ann Geriatr Med Res 2018;22:73-9.
21. Gosselin K, Troosters T, Decramer M. Distribution of muscle weakness in patients with stable chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2000;20:333-60.
22. Filipac C, Bartolome C, Miguel D, Victor PP. Longitudinal changes in handgrip strength, hyperinflation, and 6-minute walk distance in patients with COPD and a control group. Chest 2015;148:986-94.
23. Martinez CH, Diaz AA, Meldrum CA, McDonald MN, Murray S, Kinney GL, et al. Handgrip strength in chronic obstructive pulmonary disease. Associations with acute exacerbations and body composition. Ann Am Thorac Soc 2017;14:1638-45.
24. Marino DM, Marrara KT, Ike D, De Oliveira AD Jr., Jamami M, Di Lorenzo VA. Study of peripheral muscle strength and severity indexes in individuals with chronic obstructive pulmonary disease. Physiother Res Int 2010;15:135-43.

25. Jeong M, Kang HK, Song P, Park HK, Jung H, Lee SS, et al. Hand grip strength in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017;12:2385-90.

26. Schols AM, Breukhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005;82:53-9.

27. Hanania NA, Sharma G, Sharafkhaneh A. COPD in the elderly patient. Semin Respir Crit Care Med 2010;31:596-606.

28. Bone AE, Hepgl N, Kon S, Maddocks M. Sarcopenia and frailty in chronic respiratory disease. Chron Respir Dis 2017;14:85-99.

29. Troosters T, Demeyer H, Hornikx M, Camillo CA, Janssens W. Pulmonary rehabilitation. Clin Chest Med 2014;35:241-9.

30. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: Consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2014;15:95-101.

31. Gea J, Pascual S, Casadevall C, Orozco-Levi M, Barreiro E. Muscle dysfunction in chronic obstructive pulmonary disease: Update on causes and biological findings. J Thorac Dis 2015;7:E418-38.

32. Corwin EJ, Klein LC, Rickelman K. Predictors of fatigue in healthy young adults: Moderating effects of cigarette smoking and gender. Biol Res Nurs 2002;3:222-33.

33. Zhang J, Liu Y, Shi J, Larson DF, Watson RR. Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. Exp Biol Med (Maywood) 2002;227:823-9.

34. Eagan TM, Gabazza EC, D’Alessandro-Gabazza C, Gil-Bernabe P, Aoki S, Hardie JA, et al. TNF-α is associated with loss of lean body mass only in already cachectic COPD patients. Respir Res 2012;13:48.

35. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm (Lond) 2010;7:29.

36. Balachandran A, Krawczyk SN, Potiaumpai M, Signorile JF. High-speed circuit training vs hypertrophy training to improve physical function in sarcopenic obese adults: A randomized controlled trial. Exp Gerontol 2014;60:64-71.

37. Kim HK, Suzuki T, Saito K, Yoshida H, Kobayashi H, Kato H, et al. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: A randomized controlled trial. J Am Geriatr Soc 2012;60:16-23.

38. Liao CD, Tsauo JY, Lin LF, Huang SW, Ku JW, Chou LC, et al. Effects of elastic resistance exercise on body composition and physical capacity in older women with sarcopenic obesity: A CONSORT-compliant prospective randomized controlled trial. Medicine (Baltimore) 2017;96:e7115.

39. Kim H, Kim M, Kojima N, Fujino K, Hoso E, Kobayashi H, et al. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: A randomized controlled trial. J Am Med Dir Assoc 2016;17:1011-9.

40. Sugiyama Y, Asai K, Yoshida S, Kyomoto Y, Kawamoto T, Sato K, et al. Relationships between sarcopenia and pulmonary function, exercise capacity, and prognosis in patients with COPD. Eur Respir J 2016;48:PA5028.

41. Gonzalez MC, Heymsfield SB. Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia: What are we really estimating? J Cachexia Sarcopenia Muscle 2017;8:187-9.